Indicated for: prostate cancer; breast cancer; endometriosis
Route of administration: intramuscular
Substance: triptorelin (GnRH agonist)
ATC: L02AE04 (Antineoplastic and immunomodulating agents | Hormones and related agents | Gonadotropin releasing hormone analogues)
Triptorelin is a synthetic analog of gonadotropin-releasing hormone (GnRH) used in the treatment of hormone-dependent conditions such as prostate cancer, endometriosis, and precocious puberty. It works by inhibiting the secretion of gonadotropins (LH and FSH), leading to decreased testosterone levels in men and estrogen levels in women.
Triptorelin is administered as intramuscular or subcutaneous injections, usually at intervals of 1, 3, or 6 months, depending on the therapeutic indication. It is commonly used in hormone suppression therapy to slow the progression of prostate cancer or to control symptoms of endometriosis.
Common side effects include hot flashes, decreased libido, fatigue, and headaches. In rare cases, allergic reactions or long-term bone density loss may occur. Regular monitoring is essential to evaluate treatment efficacy and manage side effects.
Triptorelin is an effective and well-tolerated medication for managing hormone-dependent conditions, helping to improve patients' quality of life.